+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients



A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients



Transplant International 11(3): 231-236



Acute steroid-resistant rejection episodes in kidney allograft recipients require treatment with antilymphocyte antibodies. Monoclonal anti-CD3 and polyclonal antilymphocyte antibodies have been widely used but seldom compared. Recent data have suggested that these antibodies could be used at reduced doses without jeopardizing their efficacy. In this study, we randomized renal transplant recipients who encountered a first acute steroid-resistant rejection episode to low-dose ATG or low-dose OKT3 treatment. Sixty patients were enrolled in the study. They received prophylactic immunosuppression with cyclosporin, azathioprine, and prednisolone. Treatment of biopsy-proven rejection consisted of a 10-day course of either ATG (n = 31) or OKT3 (n = 29). The total ATG dose was 484 +/- 110 mg, i.e., 0.75 mg/kg per day. The total OKT3 dose was 32 +/- 4 mg, i.e., 0.05 mg/kg per day. We compared reversion of rejection, side effects, immunodepression, and graft function. Reversion of rejection was similar in the two groups, although we noted a trend in favor of ATG. Results were 3% vs 10% early graft failures, 13% vs 23% overall graft failures, 28% vs 38% 3-month actuarial incidence of rebound rejection, and 89% vs 81% 1-year graft survival rate in the ATG and OKT3 groups, respectively. Tolerance was worse in the OKT3 group due to the first-dose syndrome. Infections and cancers occurred with the same frequency. ATG resulted in a deeper and longer decrease in peripheral lymphocyte subsets. Graft function was similar in the two groups. We conclude that low-dose ATG and low-dose OKT3 are equally effective in reversing steroid-resistant acute rejection. Tolerance was better with ATG, which also gave a more potent and longlasting immunodepression. The use of reduced doses of ATG and OKT3 did not appear to lessen their efficacy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045102190

Download citation: RISBibTeXText

PMID: 9638854

DOI: 10.1007/s001470050133


Related references

Randomized prospective study comparing low-dose OKT3 of low-dose antithymocyte globulins for treatment of the first acute rejection of kidney allografts. Nephrology Dialysis Transplantation 11(6): A276, 1996

High or low dose steroid therapy for acute renal transplant rejection after prophylactic OKT3 treatment: a prospective randomized study. Transplant International 5(Suppl. 1): S437-S439, 1992

High or low dose steroid therapy for acute renal transplant rejection after prophylactic Okt3 treatment: a prospective randomized study. Transplant International 5: S437-S439, 1992

Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients. Transplantation Proceedings 25(4): 2574, 1993

A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 71(1): 53-58, 2001

A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Transplantation 69(11): 2374-2381, 2000

A prospective clinical trial comparing low dose OKT3 prophylaxis and prednisolone cyclosporine treatment in renal transplant recipients. Kidney International 43(4): 971-972, 1993

High dose vs low dose steroids for acute rejection episodes in renal transplant recipients. Drug Intelligence & Clinical Pharmacy: 482-483, 1981

Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts. Transplantation Proceedings 26(1): 273-274, 1994

OKT3 treatment of steroid-resistant rejection in pediatric liver transplant recipients. Journal of Pediatric Gastroenterology and Nutrition 14(1): 86-91, 1992

Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Transplantation Proceedings 28(2): 1014, 1996

Low-dose OKT3 with mycophenolate versus standard-dose OKT3 without mycophenolate induction in high risk kidney transplant recipients. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 664A, 1998

FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. Transplantation Proceedings 28(6): 3166-3168, 1996

Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. Transplantation Proceedings 29(7): 2955-2957, 1997

A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients. Transplantation 97(4): 470-473, 2014